Contezolid(MRX-I)
99%
- Product Code: 166620
CAS:
1112968-42-9
| Molecular Weight: | 408.33 g./mol | Molecular Formula: | C₁₈H₁₅F₃N₄O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, sealed, dry, light-proof |
Product Description:
Contezolid (MRX-I) is an oxazolidinone antibiotic developed primarily for the treatment of infections caused by Gram-positive bacteria, especially those resistant to other antibiotics. It is particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant strains of Mycobacterium tuberculosis.
One of its key applications is in the management of complicated skin and soft tissue infections (cSSTIs), where its mechanism of action inhibits bacterial protein synthesis without cross-resistance to other classes of antibiotics. Due to its favorable pharmacokinetic profile, it achieves high tissue penetration, making it suitable for infections localized in skin and deep tissues.
Contezolid also shows promise in treating drug-resistant tuberculosis, especially in cases where linezolid—the first-line oxazolidinone—is limited by toxicity with long-term use. Contezolid appears to have a reduced risk of myelosuppression and peripheral neuropathy, offering a safer alternative for extended therapy.
Its development addresses the growing need for new agents against multidrug-resistant pathogens, positioning it as a valuable option in hospital and community settings where antibiotic resistance is a major concern.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White to Off-White Solid |
| Purity (%) | 98.5-100% |
| Infrared Spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1mg | 10-20 days | ฿30,000.00 |
+
-
|
Contezolid(MRX-I)
Contezolid (MRX-I) is an oxazolidinone antibiotic developed primarily for the treatment of infections caused by Gram-positive bacteria, especially those resistant to other antibiotics. It is particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant strains of Mycobacterium tuberculosis.
One of its key applications is in the management of complicated skin and soft tissue infections (cSSTIs), where its mechanism of action inhibits bacterial protein synthesis without cross-resistance to other classes of antibiotics. Due to its favorable pharmacokinetic profile, it achieves high tissue penetration, making it suitable for infections localized in skin and deep tissues.
Contezolid also shows promise in treating drug-resistant tuberculosis, especially in cases where linezolid—the first-line oxazolidinone—is limited by toxicity with long-term use. Contezolid appears to have a reduced risk of myelosuppression and peripheral neuropathy, offering a safer alternative for extended therapy.
Its development addresses the growing need for new agents against multidrug-resistant pathogens, positioning it as a valuable option in hospital and community settings where antibiotic resistance is a major concern.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :